The shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has been pegged with a rating of Outperform by SVB Leerink in its latest research note that was published on July 22nd, 2019. The research company has also assigned a $5 price target. SVB Leerink wasn’t the only research firm that published a report of Amneal Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. RBC Capital Mkts advised investors in its research note published on July 11th, 2019, to Sector Perform the AMRX stock while also putting a $6 price target. The stock had earned Overweight rating from Piper Jaffray when it published its report on July 8th, 2019. The stock was given Equal Weight rating by Barclays in its report released on June 11th, 2019, the day when the price target on the stock was placed at $9. Raymond James was of a view that AMRX is Strong Buy in its latest report on May 21st, 2019 while giving it a price target of $13. SunTrust thinks that AMRX is worth Buy rating. This was contained in the firm’s report on March 20th, 2019 in which the stock’s price target was also moved to $16.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 5 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $5.23. The price of the stock the last time has dropped by -6.25% from its Week high price while it is dropped higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 18.23.
The shares of the company dipped by -6.61% during the trading session on Thursday, reaching a low of $2.38 while ending the day at $2.40. During the trading session, a total of 1.86 million shares were traded which represents a 3.08% incline from the average session volume which is 1.92M shares. AMRX had ended its last session trading at 2.57. Amneal Pharmaceuticals, Inc. currently has a market cap of $737.57M while its P/E earnings growth sits at 0.40, with a beta of 1.44. Amneal Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 5.88, while its quick ratio hovers at 1.40. AMRX 52-week low price stands at $2.56 while its 52-week high price is $24.48.
The company in its last quarterly report recorded $0.14 earnings per share which is below the $0.18 predicted by most analysts. The Amneal Pharmaceuticals, Inc. generated $446.12 million in revenue during the last quarter, which is slightly higher than the $438.76 million predicted by analysts. In the second quarter last year, the firm recorded $0.33 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -135.71%. Amneal Pharmaceuticals, Inc. has the potential to record -0.52 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Jefferies published a research note on August 5th, 2019 where it informed investors and clients that Tencent Music Entertainment Group (NYSE:TME) is now rated as Buy. RBC Capital Mkts also rated TME as Downgrade on July 11th, 2019, with its price target of $6 suggesting that TME could surge by 20.73% from its current share price. Even though the stock has been trading at $13.76/share, analysts expect it to surge higher by -0.22% to reach $17.32/share. It started the day trading at $14.01 and traded between $13.70 and $13.73 throughout the trading session.
The stock has a high of $19.97 for the year while the low is $11.81. The company’s P/E ratio currently sits at 80.76, while the P/B ratio is 3.99. At the moment, only of Tencent Music Entertainment Group shares were sold short. The company’s average trading volume currently stands at 6.21M shares, which means that the short-interest ratio is just 6.19 days. Over the past seven days, the company moved, with its shift of -6.60%. Looking further, the stock has dropped -3.58% over the past 90 days while it lost -19.19% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more TME shares, increasing its portfolio by +5,002.34% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 57,681,391 shares in the last quarter, thus it now holds 58,834,480 shares of TME, with a total valuation of $839,568,030. Baillie Gifford Co meanwhile bought more TME shares in the recently filed quarter, changing its stake to $156,208,396 worth of shares.
Similarly, William Blair Investment Manageme increased its Tencent Music Entertainment Group shares by +17.16% during the recently filed quarter. After buying 948,641 shares in the last quarter, the firm now controls 6,477,265 shares of Tencent Music Entertainment Group which are valued at $92,430,572. In the same vein, Capital Research Management Co decreased its Tencent Music Entertainment Group shares by during the most recent reported quarter. The firm sold -773,742 shares during the quarter which decreased its stakes to 6,365,245 shares and is now valued at $90,832,046. Following these latest developments, around of Tencent Music Entertainment Group stocks are owned by institutional investors and hedge funds.